Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Jan 7;19(1):57-64.
doi: 10.3748/wjg.v19.i1.57.

Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification

Affiliations
Comparative Study

Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification

Shira Zelber-Sagi et al. World J Gastroenterol. .

Abstract

Aim: To compare noninvasive methods presently used for steatosis detection and quantification in nonalcoholic fatty liver disease (NAFLD).

Methods: Cross-sectional study of subjects from the general population, a subgroup from the First Israeli National Health Survey, without excessive alcohol consumption or viral hepatitis. All subjects underwent anthropometric measurements and fasting blood tests. Evaluation of liver fat was performed using four noninvasive methods: the SteatoTest; the fatty liver index (FLI); regular abdominal ultrasound (AUS); and the hepatorenal ultrasound index (HRI). Two of the noninvasive methods have been validated vs liver biopsy and were considered as the reference methods: the HRI, the ratio between the median brightness level of the liver and right kidney cortex; and the SteatoTest, a biochemical surrogate marker of liver steatosis. The FLI is calculated by an algorithm based on triglycerides, body mass index, γ-glutamyl-transpeptidase and waist circumference, that has been validated only vs AUS. FLI < 30 rules out and FLI ≥ 60 rules in fatty liver.

Results: Three hundred and thirty-eight volunteers met the inclusion and exclusion criteria and had valid tests. The prevalence rate of NAFLD was 31.1% according to AUS. The FLI was very strongly correlated with SteatoTest (r = 0.91, P < 0.001) and to a lesser but significant degree with HRI (r = 0.55, P < 0.001). HRI and SteatoTest were significantly correlated (r = 0.52, P < 0.001). The κ between diagnosis of fatty liver by SteatoTest (≥ S2) and by FLI (≥ 60) was 0.74, which represented good agreement. The sensitivity of FLI vs SteatoTest was 85.5%, specificity 92.6%, positive predictive value (PPV) 74.7%, and negative predictive value (NPV) 96.1%. Most subjects (84.2%) with FLI < 60 had S0 and none had S3-S4. The κ between diagnosis of fatty liver by HRI (≥ 1.5) and by FLI (≥ 60) was 0.43, which represented only moderate agreement. The sensitivity of FLI vs HRI was 56.3%, specificity 86.5%, PPV 57.0%, and NPV 86.1%. The diagnostic accuracy of FLI for steatosis > 5%, as predicted by SteatoTest, yielded an area under the receiver operating characteristic curve (AUROC) of 0.97 (95% CI: 0.95-0.98). The diagnostic accuracy of FLI for steatosis > 5%, as predicted by HRI, yielded an AUROC of 0.82 (95% CI: 0.77-0.87). The κ between diagnosis of fatty liver by AUS and by FLI (≥ 60) was 0.48 for the entire sample. However, after exclusion of all subjects with an intermediate FLI score of 30-60, the κ between diagnosis of fatty liver by AUS and by FLI either ≥ 60 or < 30 was 0.65, representing good agreement. Excluding all the subjects with an intermediate FLI score, the sensitivity of FLI was 80.3% and the specificity 87.3%. Only 8.5% of those with FLI < 30 had fatty liver on AUS, but 27.8% of those with FLI ≥ 60 had normal liver on AUS.

Conclusion: FLI has striking agreement with SteatoTest and moderate agreements with AUS or HRI. However, if intermediate values are excluded FLI has high diagnostic value vs AUS.

Keywords: Agreement; Fatty liver index; Hepatorenal ultrasound index; Screening; Sensitivity; Specificity; SteatoTest; Steatosis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ultrasound image of the liver and the right kidney cortex with graphic representation of the histogram in the region of interest rectangle. HIST1 is the histogram of the liver and HIST2 is the histogram of the right kidney cortex. The median histogram (MD) 1 of the liver is 102.3 and the MD2 of the kidney cortex is 50.1, yielding an HRI of 2.04.
Figure 2
Figure 2
Correlation of fatty liver index with the reference methods. A: SteatoTest; B: Hepatorenal ultrasound index (HRI). FLI: Fatty liver index.
Figure 3
Figure 3
Distribution of SteatoTest and hepatorenal ultrasound index by fatty liver index above and below 60. A: SteatoTest; B: Hepatorenal ultrasound index (HRI). The box represents the interquartile range. The line across the box indicates the median. The “whiskers” are lines that extend from the box to the highest and lowest values, excluding outliers (defined as observations greater than 1.5 interquartile ranges). FLI: Fatty liver index.
Figure 4
Figure 4
Receiver operating characteristic curves for diagnostic accuracy of fatty liver index vs SteatoTest or hepatorenal ultrasound index. A: SteatoTest; B: Hepatorenal ultrasound index (HRI). Comparing fatty liver index (FLI) to SteatoTest ≥ S2, area under the receiver operating characteristic curve (AUROC) was 0.97 (95% CI: 0.95-0.98). Comparing FLI to HRI ≥ 1.5, AUROC was 0.82 (95% CI: 0.77-0.87). Receiver operating characteristic curve of sensitivity (true-positive fraction) plotted against 1- specificity (false-positive fraction) of the FLI for diagnosis of steatosis.

Similar articles

Cited by

References

    1. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28:162–168. - PubMed
    1. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, Charatcharoenwitthaya P, Topping JH, Bugianesi E, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54:1208–1216. - PMC - PubMed
    1. Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–117. - PubMed
    1. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol. 2004;3:63–65. - PubMed
    1. Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int. 2006;26:856–863. - PubMed

Publication types

MeSH terms